Cyclerion Therapeutics Inc (CYCN) — Cash Flow-to-Debt Ratio
Cyclerion Therapeutics Inc (CYCN) has a Cash Flow-to-Debt Ratio of -1.75x as of December 2025, meaning its operating cash flow of $-1.58 Million could theoretically repay -2% of its total liabilities ($900.00K) in one year. See how much free cash does Cyclerion Therapeutics Inc generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cyclerion Therapeutics Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Cyclerion Therapeutics Inc across 10 annual periods. Also explore CYCN year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Cyclerion Therapeutics Inc (2016–2025)
Year-by-year debt coverage analysis for Cyclerion Therapeutics Inc. For market capitalisation and broader financial context, see Cyclerion Therapeutics Inc (CYCN) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.68x | $-3.31 Million | $900.00K | ▲ +38.4% |
| 2024 | -5.98x | $-4.33 Million | $725.00K | ▲ +41.3% |
| 2023 | -10.18x | $-21.25 Million | $2.09 Million | ▼ -91.3% |
| 2022 | -5.32x | $-40.61 Million | $7.63 Million | ▼ -61.6% |
| 2021 | -3.29x | $-36.52 Million | $11.09 Million | ▼ -154.0% |
| 2020 | -1.30x | $-72.49 Million | $55.88 Million | ▼ -12.6% |
| 2019 | -1.15x | $-102.22 Million | $88.75 Million | ▲ +78.9% |
| 2018 | -5.46x | $-97.50 Million | $17.85 Million | ▲ +5.6% |
| 2017 | -5.79x | $-81.22 Million | $14.04 Million | ▼ -23.4% |
| 2016 | -4.69x | $-49.87 Million | $10.64 Million | — |